PR
PVLA

PSP Research’s Palvella Therapeutics PVLA Stock Holding History

PSP Research’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,084
Closed -$532K – 104
2025
Q4 		$532K Buy
+5,084
New +$434K 0.47% 38

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PSP Research's PVLA Position: Q1 2026 in Review

PSP Research sold out of Palvella Therapeutics (PVLA) in Q1 2026, closing a stake of 5,084 shares — an estimated $532K sold.

PSP Research first reported a position in PVLA in Q4 2025 and held it in 1 quarter. The position peaked at $532K in Q4 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • PSP Research reported no remaining Palvella Therapeutics position as of Q1 2026 after selling out during the quarter.
  • PSP Research sold 5,084 Palvella Therapeutics shares in Q1 2026, an estimated $532K.
  • PSP Research first reported a position in Palvella Therapeutics in Q4 2025 and held it in 1 quarter.
  • PSP Research's Palvella Therapeutics position peaked at $532K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.